Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
73
Stocks News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,820.30 | 6.40 | -0.07% |
CAC 40 | 7,829.29 | 72.96 | -0.92% |
DAX 40 | 24,255.31 | 201.50 | -0.82% |
Dow JONES (US) | 44,371.51 | 279.13 | -0.63% |
FTSE 100 | 8,941.12 | 34.54 | -0.38% |
HKSE | 24,139.57 | 111.20 | 0.46% |
NASDAQ | 20,585.53 | 45.14 | -0.22% |
Nikkei 225 | 39,569.68 | 76.68 | -0.19% |
NZX 50 Index | 12,686.68 | 73.52 | -0.58% |
S&P 500 | 6,259.75 | 20.71 | -0.33% |
S&P/ASX 200 | 8,580.10 | 9.10 | -0.11% |
SSE Composite Index | 3,510.18 | 0.50 | 0.01% |